Ms. Alexander et al., ONCE-DAILY CONTROLLED-RELEASE REMOXIPRIDE IS EQUIEFFECTIVE WITH TWICE-DAILY IMMEDIATE-RELEASE REMOXIPRIDE IN THE TREATMENT OF SCHIZOPHRENIA, J PSYCHOPH, 7(3), 1993, pp. 276-282
A controlled release (CR) formulation of remoxipride (Roxiam(R), Astra
) given once-daily was compared to immediate release (IR) remoxipride.
given twice-daily, with respect to efficacy and tolerability, in a 4-
week multicentre parallel-group dose titration (200-600 mg/day) study
with acutely ill schizophrenic patients. Forty-three patients received
remoxipride CR (mean dose 344 mg/day) and 49 patients received remoxi
pride IR (mean dose 346 mg/day). Efficacy was assessed using the Kolak
owska version of the Brief Psychiatric Rating Scale (BPRS score of gre
ater-than-or-equal-to 18 points at entry) and the Clinical Global Impr
ession scale (CGI), while extrapyramidal symptoms were rated using the
Simpson and Angus scale. Both formulations of remoxipride produced cl
inical improvement, with the BPRS median total score falling from 35 a
t baseline to 16 at last rating in the remoxipride CR group, and from
33 to 12.5 in the remoxipride IR group. More than 70% of the patients
in both groups were assessed as 'much improved' or 'very much improved
' according to the CGI scale. Both formulations of remoxipride were we
ll-tolerated, with a low incidence of treatment-emergent adverse sympt
oms, including extrapyramidal side effects. No statistically significa
nt differences were detected between the treatment groups with regard
to efficacy, safety or tolerability.